BLI Banque de Luxembourg Investments Buys Shares of 50,000 DexCom, Inc. $DXCM

BLI Banque de Luxembourg Investments bought a new stake in DexCom, Inc. (NASDAQ:DXCM) during the fourth quarter, Holdings Channel reports. The institutional investor bought 50,000 shares of the medical device company’s stock, valued at approximately $3,354,000.

A number of other hedge funds have also made changes to their positions in DXCM. CVA Family Office LLC grew its position in DexCom by 48.5% during the fourth quarter. CVA Family Office LLC now owns 450 shares of the medical device company’s stock valued at $30,000 after purchasing an additional 147 shares in the last quarter. MCF Advisors LLC purchased a new stake in DexCom in the 4th quarter worth approximately $32,000. ORG Partners LLC lifted its position in DexCom by 124.3% in the 4th quarter. ORG Partners LLC now owns 507 shares of the medical device company’s stock worth $34,000 after buying an additional 281 shares in the last quarter. Spire Wealth Management boosted its stake in shares of DexCom by 113.8% during the 4th quarter. Spire Wealth Management now owns 573 shares of the medical device company’s stock valued at $38,000 after buying an additional 305 shares during the period. Finally, Aventura Private Wealth LLC purchased a new position in shares of DexCom during the 4th quarter valued at $43,000. 97.75% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at DexCom

In other DexCom news, insider Kevin R. Sayer sold 26,759 shares of DexCom stock in a transaction on Thursday, May 21st. The shares were sold at an average price of $72.00, for a total transaction of $1,926,648.00. Following the sale, the insider owned 382,482 shares in the company, valued at $27,538,704. The trade was a 6.54% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Jon Brown sold 1,700 shares of DexCom stock in a transaction dated Wednesday, April 15th. The shares were sold at an average price of $63.04, for a total transaction of $107,168.00. Following the sale, the executive vice president owned 111,204 shares in the company, valued at approximately $7,010,300.16. This trade represents a 1.51% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 42,694 shares of company stock valued at $3,029,267 in the last ninety days. 0.28% of the stock is owned by company insiders.

DexCom Stock Performance

Shares of NASDAQ DXCM opened at $78.19 on Wednesday. DexCom, Inc. has a 12 month low of $54.11 and a 12 month high of $89.98. The business’s 50 day moving average is $65.36 and its two-hundred day moving average is $67.28. The company has a market cap of $30.17 billion, a P/E ratio of 33.41, a P/E/G ratio of 1.20 and a beta of 1.45. The company has a quick ratio of 1.64, a current ratio of 1.95 and a debt-to-equity ratio of 0.42.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings results on Thursday, April 30th. The medical device company reported $0.56 earnings per share for the quarter, beating analysts’ consensus estimates of $0.47 by $0.09. The firm had revenue of $1.19 billion during the quarter, compared to the consensus estimate of $1.17 billion. DexCom had a net margin of 19.31% and a return on equity of 33.33%. The business’s revenue was up 15.0% on a year-over-year basis. During the same period in the prior year, the firm earned $0.32 EPS. On average, equities analysts expect that DexCom, Inc. will post 2.57 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on the stock. William Blair raised shares of DexCom to a “strong-buy” rating in a research note on Friday, May 15th. Sanford C. Bernstein set a $77.00 target price on DexCom in a research note on Friday, May 1st. Barclays reaffirmed an “underweight” rating and issued a $64.00 target price (down from $67.00) on shares of DexCom in a research report on Monday, May 18th. Mizuho set a $85.00 price target on DexCom and gave the stock an “outperform” rating in a research note on Tuesday. Finally, Raymond James Financial reiterated a “strong-buy” rating and set a $91.00 price target on shares of DexCom in a report on Monday. Three investment analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $83.46.

DexCom Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.